Rain Therapeutics Inc.
Net BuyingRAIN·US·🇺🇸 US
82%buys·18%sales
997 transactions$649.8MTotal buys·471 buys
$7.6MTotal sells·106 sells
4141 insiders
Last: Sep 12, 2025
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Sep 12, 25 | DICKERSON LYMAN B | Sell | $28K | |
| Sep 11, 25 | DICKERSON LYMAN B | Sell | $2K | |
| Sep 10, 25 | DICKERSON LYMAN B | Sell | $1K | |
| Sep 9, 25 | DICKERSON LYMAN B | Sell | $10K | |
| Sep 5, 25 | Seidl Randy | Grant | - | |
| Feb 6, 25 | DACIER PAUL T | Buy | $150K | |
| Jan 29, 25 | You Harry L. | Grant | $500K | |
| Dec 31, 24 | You Harry L. | Grant | - | |
| Dec 31, 24 | DICKERSON LYMAN B | Grant | $200K | |
| Dec 31, 24 | DACIER PAUL T | Buy | $100K |
Rain Therapeutics Inc. has seen a surge in insider activity with 4 transactions in the last 30 days, compared to a monthly average of 1. Total insider buying volume stands at $649.8M, while selling volume is $7.6M. Overall insider sentiment is bullish (82% purchases).
Rain Therapeutics Inc. (RAIN) has recorded 997 insider operations, including 471 open-market purchases ($649.8M), 106 sales ($7.6M) and 420 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bullish (82% purchases).
Rain Therapeutics Inc. shows moderate insider activity with 4 active months out of the last 12, typical of a company whose trading windows are concentrated around financial disclosures.
Among the most active insiders are Seidl Randy (CEO), Vellanki Avanish (CEO) & BRYCE RICHARD PAUL (C SUITE), with respectively 72, 19, 66 transactions.
Across all 997 recorded transactions, the breakdown by type is: buys (471, 47%), exercise (234, 23%), grant (124, 12%), sales (106, 11%), disposition (60, 6%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Rain Therapeutics Inc. has recorded 997 insider operations in total, including 471 open-market purchases ($649.8M), 106 sales ($7.6M) and 420 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on September 12, 2025.
Insiders at Rain Therapeutics Inc. are currently net buyers, with 82% purchases and 18% sales across all reported transactions. Total buy volume is $649.8M versus $7.6M in sales, indicating a bullish insider sentiment.
InsiderLens tracks 41 insiders at Rain Therapeutics Inc. (RAIN). Seidl Randy (CEO, 72 tx), Vellanki Avanish (CEO, 19 tx), BRYCE RICHARD PAUL (C SUITE, 66 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for RAIN is bullish, based on a 82% buy ratio across 577 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Rain Therapeutics Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.